600511 國藥股份
按盤價 
29.600 -0.120 (-0.404%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 25,633,951 | 3.54% | 50,597,450 | 49,696,046 | 45,498,584 | 46,468,603 | |
| 減：營業總成本 | 24,641,402 | 4.30% | 48,403,887 | 47,194,089 | 43,218,513 | 44,351,267 | |
| 其中:營業成本 | 24,060,478 | 4.60% | 47,002,226 | 45,704,776 | 41,676,318 | 42,837,500 | |
| 財務費用 | (12,458) | -76.35% | (68,030) | (126,127) | (28,840) | (18,342) | |
| 資產減值損失 | (8,207) | 102.52% | (1,066) | 389 | (5,140) | (17,588) | |
| 公允價值變動收益 | -- | -- | (18,202) | 10,817 | -- | -- | |
| 投資收益 | 293,601 | 22.17% | 514,166 | 358,952 | 291,622 | 283,351 | |
| 其中：對聯營企業和合營企業的投資收益 | 272,402 | 11.98% | 515,180 | 456,539 | 380,800 | 380,222 | |
| 營業利潤 | 1,229,119 | -7.56% | 2,677,422 | 2,944,358 | 2,694,923 | 2,447,274 | |
| 利潤總額 | 1,226,580 | -6.92% | 2,653,612 | 2,930,890 | 2,687,886 | 2,444,806 | |
| 減：所得稅費用 | 235,097 | -7.50% | 523,832 | 596,420 | 559,181 | 516,303 | |
| 淨利潤 | 991,483 | -6.79% | 2,129,781 | 2,334,471 | 2,128,705 | 1,928,503 | |
| 減：非控股權益 | 42,936 | -32.02% | 129,654 | 188,472 | 164,648 | 174,418 | |
| 股東淨利潤 | 948,547 | -5.19% | 2,000,127 | 2,145,999 | 1,964,058 | 1,754,084 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 1.257 | -5.20% | 2.651 | 2.844 | 2.603 | 2.325 | |
| 每股派息 (元) * | -- | -- | 0.800 | 0.854 | 0.782 | 0.700 | |
| 每股淨資產 (元) * | 23.159 | 8.37% | 22.701 | 20.909 | 18.840 | 16.938 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 29/08/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
